Our portfolio

Arthrogen

Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis. Their approach focuses on intra-articular delivery of therapeutic genes for sustained local treatment with minimal systemic side effects. Using adeno-associated virus (AAV) vectors, they are developing and validating new vectors and therapeutic genes, with plans to move into clinical trials in collaboration with AMC and DBAJ.

Industry: Biotechnology, Gene Therapy, Rheumatology

Want to get in contact about Arthrogen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Engineering antibodies to treat neurodegenerative and immune diseases.
AI-driven stroke treatment modeling for thrombectomy device development.
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Adding the size dimension to optical spectroscopy.
Engineering antibodies to treat neurodegenerative and immune diseases.
AI-driven stroke treatment modeling for thrombectomy device development.
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Adding the size dimension to optical spectroscopy.